Company Profile

Calviri Inc
Profile last edited on: 1/12/22      CAGE: 85Q28      UEI: QK97SNWH4G71

Business Identifier: Cancer treatment products combining immunogenic source of neoantigens with peptide array platform
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

8606 South Dorsey Lane
Tempe, AZ 85284
   (480) 205-6436
Location: Single
Congr. District: 09
County: Maricopa

Public Profile

Spun out of Arizona State University Biodesign Institute, Calviri Inc is developing diagnostic and therapeutic products aimed at fighting cancer by combining a unique, immunogenic source of neoantigens with a peptide array platform. The company is currently conducting clinical trials to demonstrate feasibiliity of prophylactic vaccines to rpevent cancer, developing early cancer diagnosis tests, and conducting vaccine trials aimed at reducing the time and expense of cancer treatments. The company's approach is based on three scientific insights and discoveries: Frameshift peptides' importance in developing effective vaccines and diagnostics; errors in RNA synthesis and processing by tumor cells being a better source of neoantigens than errors in DNA synthesis; and arrays of of frameshift peptides that can directly readout an individual's immune responses to tumor neoantigens.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 1 NIH $299,593
Project Title: A Simple Blood Test for Microsatellite Instability Status

Key People / Management

  Stephen Albert Johnston -- Founder, CEO

  Marc Wolf -- Chief Executive Officer

  Kathryn Sykes -- VP Research & Product Development